Lenvatinib as a salvage therapy for advanced metastatic medullary thyroid cancer

被引：0
|
作者：
A. Matrone
A. Prete
A. Nervo
A. Ragni
L. Agate
E. Molinaro
C. Giani
L. Valerio
E. Minaldi
A. Piovesan
R. Elisei
机构：
[1] Pisa University Hospital,Department of Clinical and Experimental Medicine, Unit of Endocrinology
[2] Azienda Ospedaliero Universitaria Città Della Salute E Della Scienza Di Torino,Department of Oncology, Oncological Endocrinology Unit
来源：
Journal of Endocrinological Investigation | 2021年 / 44卷
关键词：
Lenvatinib; Medullary thyroid cancer; Calcitonin; Carcinoembrionic antigen; Tyrosine kinase inhibitors;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2139 / 2151
页数：12
相关论文
共 50 条
  • [31] Cabozantinib approved for advanced medullary thyroid cancer
    Traynor, Kate
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2013, 70 (02) : 88 - 88
  • [32] Cabozantinib for the Treatment of Advanced Medullary Thyroid Cancer
    Nagilla, Madhavi
    Brown, Rebecca L.
    Cohen, Ezra E. W.
    ADVANCES IN THERAPY, 2012, 29 (11) : 925 - 934
  • [33] Neoadjuvant selpercatinib for advanced medullary thyroid cancer
    Jozaghi, Yelda
    Zafereo, Mark
    Williams, Michelle D.
    Gule-Monroe, Maria K.
    Wang, Jennifer
    Grubbs, Elizabeth G.
    Vaporciyan, Ara
    Hu, Mimi I.
    Busaidy, Naifa
    Dadu, Ramona
    Waguespack, Steven G.
    Subbiah, Vivek
    Cabanillas, Maria
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2021, 43 (01): : E7 - E12
  • [34] Vandetanib and the management of advanced medullary thyroid cancer
    Campbell, Michael J.
    Seib, Carolyn D.
    Gosnell, Jessica
    CURRENT OPINION IN ONCOLOGY, 2013, 25 (01) : 39 - 43
  • [35] Cabozantinib for the Treatment of Advanced Medullary Thyroid Cancer
    Madhavi Nagilla
    Rebecca L. Brown
    Ezra E. W. Cohen
    Advances in Therapy, 2012, 29 : 925 - 934
  • [36] A phase II trial of the multitargeted kinase inhibitor lenvatinib (E7080) in advanced medullary thyroid cancer (MTC).
    Schlumberger, Martin
    Jarzab, Barbara
    Cabanillas, Maria E.
    Robinson, Bruce
    Pacini, Furio
    Ball, Douglas Wilmot
    McCaffrey, Judith C.
    Newbold, Kate
    Allison, Roger
    Martins, Renato
    Licitra, Lisa F.
    Shah, Manisha H.
    Bodenner, Donald
    Elisei, Rossella
    Burmeister, Lynn A.
    Funahashi, Yasuhiro
    Sellecchia, Rita
    Andresen, Corina
    O'Brien, James P.
    Sherman, Steven I.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [37] Metastatic Medullary Thyroid Cancer (MTC): Is There a Role for Peptide Receptor Radionuclide Therapy (PRRT)?
    Hayes, A. R.
    Crawford, A.
    Al Riyami, K.
    Tang, C.
    Wild, D.
    Khoo, B.
    Caplin, M.
    Nicolas, G.
    Grossman, A. B.
    NEUROENDOCRINOLOGY, 2019, 108 : 273 - 273
  • [38] A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer
    Schlumberger, Martin
    Jarzab, Barbara
    Cabanillas, Maria E.
    Robinson, Bruce
    Pacini, Furio
    Ball, Douglas W.
    McCaffrey, Judith
    Newbold, Kate
    Allison, Roger
    Martins, Renato G.
    Licitra, Lisa F.
    Shah, Manisha H.
    Bodenner, Donald
    Elisei, Rossella
    Burmeister, Lynn
    Funahashi, Yasuhiro
    Ren, Min
    O'Brien, James P.
    Sherman, Steven I.
    CLINICAL CANCER RESEARCH, 2016, 22 (01) : 44 - 53
  • [39] Diagnostic characteristics, treatment patterns, and clinical outcomes for patients with advanced/metastatic medullary thyroid cancer
    Parikh, Rohan
    Hess, Lisa M.
    Esterberg, Elizabeth
    Bhandari, Naleen Raj
    Kaye, James A.
    THYROID RESEARCH, 2022, 15 (01)
  • [40] Teriparatide Replacement Therapy for Hypoparathyroidism During Treatment With Lenvatinib for Advanced Thyroid Cancer: A Case Report
    Porcelli, Tommaso
    Sessa, Francesca
    Caputo, Angela
    Catalini, Christian
    Salvatore, Domenico
    FRONTIERS IN ENDOCRINOLOGY, 2018, 9
12345